Monitor the shareholder vote results for the stock plan amendment, which could impact future equity dilution. The other proposals are routine and unlikely to affect operations.
FATE drugs
FATE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $1.31entry
- T+1 · 7mo ago −0.76%α −0.28% · $1.30
- T+5 · 7mo ago +37.40%α +37.00% · $1.80
- T+20 · 6mo ago +64.12%α +59.17% · $2.15
- T+60 · 4mo ago +96.95%α +92.17% · $2.58
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
FATE THERAPEUTICS INC filed a definitive proxy statement for its 2026 annual shareholder meeting, proposing the election of three Class I directors, ratification of auditors, advisory approval of executive compensation, and an increase in shares available under its stock option plan.
Key Financial Metrics
Key Facts
- Annual shareholder meeting scheduled for June 12, 2026
- Proposing election of three Class I directors: Robert S. Epstein, Karin Jooss, and Laura J. Hamill
- Proposing to increase shares available under the 2022 Stock Option and Incentive Plan
- Proposing ratification of Ernst & Young LLP as independent auditors
- Proposing non-binding advisory approval of named executive officer compensation
Financial Impact
Potential dilution from increased shares in stock option plan, magnitude undisclosed
Risk Factors
- Increased share count from stock plan amendment could lead to shareholder dilution
- Shareholder opposition to executive compensation could signal governance concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-177171 |
| Document: 0001193125-26-177171-index-headers.html | 0001193125-26-177171 |
| Document: 0001193125-26-177171-index.html | 0001193125-26-177171 |
| Document: 0001193125-26-177171.txt | 0001193125-26-177171 |
Track record
21 reports on FATE
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers